New hope for kids with tough cancers: experimental drug PEEL-224 enters trials

NCT ID NCT06721689

Recruiting now Disease control Sponsor: Theodore Laetsch Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests a new drug called PEEL-224, alone or with standard chemotherapy, in children and young adults whose solid tumors have not responded to treatment or have returned. The first part finds the safest dose, and the second part measures how well the drug combination shrinks tumors in specific cancers like neuroblastoma and rhabdomyosarcoma. About 59 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma Recurrence refractory malignant neoplasm rhabdomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY NEUROBLASTOMA REFRACTORY RHABDOMYOSARCOMA REFRACTORY SOLID TUMORS RELAPSED NEUROBLASTOMA RELAPSED RHABDOMYOSARCOMA RELAPSED SOLID TUMORS

Contacts and locations

Locations

Boston Children's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Texas Children's Hospital
RECRUITING

Houston, Texas, 77030, United States
University of California, San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Utah Hospital
NOT_YET_RECRUITING

Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.